**Supplemental Table 1.** Cox Proportional Hazards Model Results Including Adherence, Risk Estimates and 95% Confidence Intervals for Virologic Failure over 18 Months of First Line Antiretroviral Therapy (n=5547)

|  |  |  |  |
| --- | --- | --- | --- |
| **Factor** | **Hazard Ratio** | **95% CI** | **P Value** |
| Tenofovir group | 1.48 | 1.21, 1.80 | <0.001 |
| Age (years) | 0.98 | 0.97, 0.99 | 0.002 |
| Female gender | 0.93 | 0.72, 1.18 | 0.56 |
| HBV co-infection | 0.96 | 0.75, 1.23 | 0.74 |
| HCV co-infection | 1.21 | 0.88, 1.66 | 0.25 |
| CD4 (log10) | 0.49 | 0.39, 0.62 | <0.001 |
| HIV RNA (log10) | 1.15 | 1.03, 1.28 | 0.011 |
| Adherence <95% | 1.28 | 1.07, 1.54 | 0.008 |

Abbreviations: CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus.

Allrisk factors except adherence were measured at baseline.